Positive Final Data from HyCAMP Phase II Trial in Metastatic Colorectal
BRISBANE, Australia, May 29, 2007 /PRNewswire/ -- Phase II results exceed expectations - Alchemia prepares for FDA talks on HyCAMP(TM) Australian drug development company Alchemia Limited will commence discussions with the US Food and Drug Administration (FDA) following the successful conclusion...PipelineReview.com - Biotech News & Online Store - Alchemia reports ...
... Alchemia reports preliminary positive efficacy data from HyCAMP Phase II trial ... 14 of 41 (34%) HyCAMP(TM) patients compared to 5 of 35 (14%) irinotecan ...Alchemia Release: Positive Final Data from HyCAMP(TM) Phase II Trial in ...
HyCAMP(TM) exerted superior anti-cancer activity with a significantly greater ... Patients on HyCAMP(TM) were able to receive therapy for a median of three times ...Healthcare Sales & Marketing Network News: Positive Final Data from ...
Positive Final Data from HyCAMP(TM) Phase II Trial in Metastatic Colorectal Cancer (HSMN NewsFeed: Medical Devices, Pharmaceuticals and Diagnostics)Press release: Positive Final Data from HyCAMP Phase II Trial in ...
Press release: Positive Final Data from HyCAMP Phase II Trial in Metastatic Colorectal Cancer ... Read more... HyCAMP(TM) exerted superior anti-cancer ...A Randomized Phase II Trial of Irinotecan With Hyaluronan
(HYCAMP) versus Irinotecan Alone as Treatment for Patients With ... Fourteen of 41 (34%) HyCAMP patients compared with 5 of 35 (14%) irinotecan patients ...Print: Australia's Alchemia Talks To USFD On HyCAMP | PharmaAsia.com
HyCAMP exerted superior anti-cancer activity with a significantly greater number ... Patients on HyCAMP were able to receive therapy for a median of three times ...